Skip to content
JoelGalvan

JoelGalvan

View Video Stories
  • Home
  • Business
  • Culture
  • Sports
  • Home
  • Business
  • Culture
  • Sports
© https://joelgalvan.site/-All rights reserved. Theme Blognest designed by WPInterface.
  • Home
  • Therapeutics

Tag: Therapeutics

Mizuho Lifts PT on Neumora Therapeutics (NMRA) to $5 from $4, Keeps Outperform Rating
Posted in Business

Mizuho Lifts PT on Neumora Therapeutics (NMRA) to $5 from $4, Keeps Outperform Rating

Estimated read time 2 min read
Posted on July 21, 2025
by Joelgalvan

Neumora Therapeutics, Inc. (NASDAQ:NMRA) is one of the hot penny stocks to invest in now. On July 16, Mizuho analyst Graig…

Learn More Leave a Comment on Mizuho Lifts PT on Neumora Therapeutics (NMRA) to $5 from $4, Keeps Outperform Rating
BTIG Reiterates a Buy Rating on Denali Therapeutics (DNLI) With a $32 Price Target
Posted in Business

BTIG Reiterates a Buy Rating on Denali Therapeutics (DNLI) With a $32 Price Target

Estimated read time 2 min read
Posted on July 18, 2025
by Joelgalvan

Denali Therapeutics, Inc. (NASDAQ:DNLI) is one of the best oversold NASDAQ stocks to buy now. In a report released on…

Learn More Leave a Comment on BTIG Reiterates a Buy Rating on Denali Therapeutics (DNLI) With a $32 Price Target
UBS Trims Price Target but Stays Bullish on United Therapeutics (UTHR)
Posted in Business

UBS Trims Price Target but Stays Bullish on United Therapeutics (UTHR)

Estimated read time 2 min read
Posted on July 12, 2025
by Joelgalvan

United Therapeutics Corp. (NASDAQ:UTHR) is one of the 11 best debt-free stocks to invest in right now. The company boasts a…

Learn More Leave a Comment on UBS Trims Price Target but Stays Bullish on United Therapeutics (UTHR)
Morgan Stanley Assumes Coverage of Kymera Therapeutics (KYMR) Stock with Overweight Rating
Posted in Business

Morgan Stanley Assumes Coverage of Kymera Therapeutics (KYMR) Stock with Overweight Rating

Estimated read time 2 min read
Posted on July 11, 2025
by Joelgalvan

Kymera Therapeutics, Inc. (NASDAQ:KYMR) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds. Morgan Stanley…

Learn More Leave a Comment on Morgan Stanley Assumes Coverage of Kymera Therapeutics (KYMR) Stock with Overweight Rating
Akebia Therapeutics (AKBA) Grants Stock Options to New Employees
Posted in Business

Akebia Therapeutics (AKBA) Grants Stock Options to New Employees

Estimated read time 2 min read
Posted on June 30, 2025
by Joelgalvan

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the 10 best healthcare penny stocks to buy according to analysts. On June…

Learn More Leave a Comment on Akebia Therapeutics (AKBA) Grants Stock Options to New Employees
Edgewise Therapeutics price target lowered to $35 from $40 at Wedbush
Posted in Business

Edgewise Therapeutics price target lowered to $35 from $40 at Wedbush

Estimated read time 1 min read
Posted on June 28, 2025
by Joelgalvan

Wedbush analyst Laura Chico lowered the firm’s price target on Edgewise Therapeutics (EWTX) to $35 from $40 and keeps an…

Learn More Leave a Comment on Edgewise Therapeutics price target lowered to $35 from $40 at Wedbush
Chardan Initiates Coverage of Monopar Therapeutics (MNPR) Stock, Gives Buy
Posted in Business

Chardan Initiates Coverage of Monopar Therapeutics (MNPR) Stock, Gives Buy

Estimated read time 2 min read
Posted on June 28, 2025
by Joelgalvan

Monopar Therapeutics Inc. (NASDAQ:MNPR) is one of the 10 Unstoppable Stocks to Buy According to Hedge Funds. On June 23, Chardan…

Learn More Leave a Comment on Chardan Initiates Coverage of Monopar Therapeutics (MNPR) Stock, Gives Buy
Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential
Posted in Business

Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential

Estimated read time 2 min read
Posted on June 19, 2025
by Joelgalvan

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is among the best NASDAQ stocks under $50 to buy. Analysts at H.C. Wainwright have reaffirmed…

Learn More Leave a Comment on Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential
Why Summit Therapeutics Inc. (SMMT) Crashed On Wednesday
Posted in Business

Why Summit Therapeutics Inc. (SMMT) Crashed On Wednesday

Estimated read time 2 min read
Posted on June 6, 2025
by Joelgalvan

We recently published a list of Investors Are Dumping These 10 Stocks. In this article, we are going to take…

Learn More Leave a Comment on Why Summit Therapeutics Inc. (SMMT) Crashed On Wednesday
Soleno Therapeutics, Inc. (SLNO) Secures EMA Validation for PWS Treatment VYKAT XR
Posted in Business

Soleno Therapeutics, Inc. (SLNO) Secures EMA Validation for PWS Treatment VYKAT XR

Estimated read time 2 min read
Posted on May 24, 2025
by Joelgalvan

Soleno Therapeutics, Inc. (NASDAQ:SLNO) has achieved a major regulatory milestone as the European Medicines Agency (EMA) validated its Marketing Authorization…

Learn More Leave a Comment on Soleno Therapeutics, Inc. (SLNO) Secures EMA Validation for PWS Treatment VYKAT XR

Posts navigation

← Older Articles

Recent Posts

  • Canada hockey players acquitted in sexual assault case
  • Asian stocks: Asian stocks snap six days of gains, bonds steady
  • Brandon Nakashima vs Cameron Norrie preview, head-to-head, prediction, odds, and pick 
  • England vs India: Zak Crawley books Ashes spot with excellent Old Trafford innings – and reacts to Lord’s needle | Cricket News
  • Schmidt urges Wallabies to rediscover ‘edge’ to send Lions series to decider

Recent Comments

No comments to show.

Archives

  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025

Categories

  • Business
  • Culture
  • Sports
© https://joelgalvan.site/-All rights reserved. Theme Blognest designed by WPInterface.